The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index; 12 of the 29 sources its claims cite were checked for support.
Patient journey before and after a formal post-traumatic stress disorder diagnosis in adults in the United States-a retrospective claims study
Open accessAbstract
Objective: To describe post-traumatic stress disorder (PTSD)-related symptoms and frequent psychiatric comorbidities, treatments received, healthcare resource utilization (HRU), and healthcare costs pre- and post-PTSD diagnosis among adults in the United States. Methods: Adults with PTSD who received a PTSD-related pharmacological treatment (selective serotonin reuptake inhibitor [SSRI], serotonin-norepinephrine reuptake inhibitor [SNRI], atypical antipsychotic [AA]) within 24 months of the first observed PTSD diagnosis (index date) were identified using MarketScan Commercial Database (2015-2020). Study outcomes were assessed during the 6-month pre-diagnosis and 24-month post-diagnosis periods. Subgroup analyses included patients treated or not treated with AAs post-PTSD diagnosis. Results: Of the overall patients (N = 26,306; mean age at diagnosis 39.5 years; 73.3% female), 85.9% had PTSD-related symptoms and frequent psychiatric comorbidities during the 6 months pre-diagnosis. Patients treated with AAs post-PTSD diagnosis (N = 9,298) tended to have higher rates of PTSD-related symptoms and comorbidities at diagnosis than those not treated with AAs (N = 7,011). Following diagnosis, the most commonly observed first-line treatments were SSRI (67.4%), AA (23.4%), and SNRI (22.6%). The rate of PTSD-related symptoms and comorbidities, psychotherapy and pharmacological treatments received, HRU, and healthcare costs increased during the 6 months post-diagnosis relative to the 6 months pre-diagnosis and then declined over time during the 24 months post-diagnosis. Conclusions: The PTSD diagnosis was associated with increased rates of symptoms and frequent psychiatric comorbidities, psychotherapy and pharmacological treatments received, HRU, and healthcare costs, pointing to increased patient monitoring. Within 6 to 12 months after the PTSD diagnosis, these outcomes tended to reduce, perhaps as patients were obtaining targeted and effective care. © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Overview
CoChat Summary
TL;DR
In a retrospective US commercial claims analysis of 26,306 treated adults with PTSD, symptoms, treatments, healthcare utilization, and costs rose around the first observed PTSD diagnosis and then declined over 24 months post-diagnosis. The findings suggest a formal PTSD diagnosis may prompt targeted management, though the observational claims design cannot establish causality.
Key findings
- Overall sample N = 26,306; mean age at diagnosis 39.5 years, 73.3% female; 85.9% had PTSD-related symptoms and frequent psychiatric comorbidities during the 6 months pre-diagnosis. At diagnosis, 40.6% had depression, 30.1% anxiety disorders, 7.4% bipolar disorders, 7.4% substance use/abuse, and 2.6% suicidal thoughts or actions.
- Post-diagnosis, 35.3% (N = 9,295) were treated with AAs and 64.7% (N = 17,011) were not. First-line treatments were SSRI (67.4%), AA (23.4%), and SNRI (22.6%); 43.9% received their first pharmacological treatment regimen within 15 days and 77.0% within 90 days.
- Symptoms and comorbidities increased from pre-diagnosis to 0–6 months post-diagnosis and then decreased by 18–24 months; e.g., mental, behavioral, and neurodevelopmental disorders rose from 69.7% pre-diagnosis to 86.3% at 0–6 months post-diagnosis, then fell to 68.5% at 18–24 months (all p < 0.001). Psychotherapy visits rose from 50.9% pre-diagnosis to 86.0% at 0–6 months post-diagnosis, then fell to 55.9% at 18–24 months.
- Inpatient admissions increased from 12.9% pre-diagnosis to 14.4% at 0–6 months post-diagnosis and decreased to 8.0% at 18–24 months (44.3% decrease); mean total healthcare costs increased from $9,882 pre-diagnosis to $11,845 at 0–6 months post-diagnosis and decreased to $9,410 at 18–24 months (20.1% decrease). The AA-treated subgroup had less favorable outcomes at 24 months, including higher HRU and costs and more treatments.
Methods
- Retrospective database analysis using the IBM MarketScan Commercial database (October 1, 2015–September 30, 2020). Adults were included with ≥2 PTSD diagnoses (ICD-10 F43.1) on distinct dates, continuous enrollment 6 months pre- and 24 months post-index, and ≥1 prescription fill for an SSRI, SNRI, or AA within 24 months of the first observed PTSD diagnosis (index date).
- Outcomes were assessed during the 6-month pre-diagnosis period, at diagnosis, and during the 24-month post-diagnosis period in 6-month windows (0–6, 6–12, 12–18, 18–24 months). Descriptive statistics were used; Chi-square tests compared symptoms/comorbidities/treatments and Wilcoxon signed rank tests compared HRU/costs for 0–6 vs 18–24 months post-diagnosis. Subgroup analyses compared patients treated vs not treated with AAs; standardized differences ≥0.10 indicated important differences.
Limitations
- Stated: the commercially insured population may not represent the general PTSD population or individuals with public, no, or military-based insurance; claims lack clinical information such as physician notes, treatment rationale, and PTSD-severity assessments; self-medication is not captured; results were not stratified by gender or race/ethnicity; claims are subject to billing inaccuracies and missing data; and the design focused on adult pharmacologically treated patients, so undiagnosed vs diagnosed and treated vs untreated patients could not be compared.
- Evident from the text: the retrospective observational design cannot establish causality between receiving a formal PTSD diagnosis and subsequent improvements; differences in the AA-treated subgroup may reflect confounding by indication or greater disease severity rather than an effect of AA treatment itself.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 0 Not valid · 9 Not checked · 55 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“During the 6-month pre-diagnosis period, 85.9% of patients presented with PTSD-related symptoms and frequent psychiatric comorbidities, including mental, behavioral, and neurodevelopmental disorders (69.7%), physiological symptoms or reactions (58.1%), general health symptoms (23.6%), substance use (16.3%), and cognitive symptoms (10.0%).”
- Also stated in: § Abstract · plain
“85.9% had PTSD-related symptoms and frequent psychiatric comorbidities during the 6 months pre-diagnosis.”
- Also stated in: § Patient characteristics · plain
“During the 6-month pre-diagnosis period, 85.9% of patients presented with PTSD-related symptoms and frequent psychiatric comorbidities”
§ Patient journey before and after a formal posttraumatic stress disorder diagnosis in adults in the United States -a retrospective claims study > Patient characteristics
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“43.6% received SSRI”
§ Patient journey before and after a formal posttraumatic stress disorder diagnosis in adults in the United States -a retrospective claims study > Patient characteristics
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“43.9% receiving their first pharmacological treatment regimen within 15 days of the PTSD diagnosis”
§ Patient journey before and after a formal posttraumatic stress disorder diagnosis in adults in the United States -a retrospective claims study > Patient characteristics
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“7.4% had bipolar disorders”
§ Patient journey before and after a formal posttraumatic stress disorder diagnosis in adults in the United States -a retrospective claims study > Patient characteristics
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“55.9% at 18-24 months (0-6 vs 18-24 months post-diagnosis: p < 0.001; Figure 4(A)).”
§ Patient journey before and after a formal posttraumatic stress disorder diagnosis in adults in the United States -a retrospective claims study > Treatments received pre-and post-PTSD diagnosis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
25 more claims
Create a free account to see all 74 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 23
- It may state two separate claims as one. 29
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patient journey before and after a formal posttraumatic stress disorder diagnosis in adults in the United States -a retrospective claims study > Abstract
“Patients treated with AAs post-PTSD diagnosis (N ¼ 9,298) tended to have higher rates of PTSD-related symptoms and comorbidities at diagnosis than those not treated with AAs (N ¼ 7,011).”
§ Patient journey before and after a formal posttraumatic stress disorder diagnosis in adults in the United States -a retrospective claims study > Results
“A total of 26,306 treated adults with PTSD were included in the overall sample; of those, 35.3% (N ¼ 9,295) were treated with AAs and 64.7% (N ¼ 17,011) were not treated with AAs during the post-diagnosis period.”
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
(2012) · SpringerReference · doi:10.1007/springerreference_121117 · Cited by 20,570
The American Psychological Association
Langfeld, H. S. (1919) · Science · doi:10.1126/science.49.1254.51 · Cited by 7,475
Posttraumatic stress disorder: the burden to the individual and to society.
Kessler, R. C. (2000) · PubMed · Cited by 1,696
Roberts, A. L., Gilman, S. E., Breslau, J., Breslau, N., & Koenen, K. C. (2011) · Psychological Medicine · doi:10.1017/s0033291710000401 · Cited by 1,079
Post-traumatic stress disorder.
Yehuda, R., Hoge, C. W., McFarlane, A. C., Vermetten, E., Lanius, R. A., Nievergelt, C. M., Hobfoll, S. E., Koenen, K. C., Neylan, T. C., & Hyman, S. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.57 · Cited by 870 · cited 1×
“PTSD-specific clinical management of patients with PTSD may help to reduce the overall disease burden and often involves careful assessment of the nature of the trauma and provision of trauma-focused psychotherapy and/or pharmacological treatments [9,23,24].”
Background(2000) · PubMed · Cited by 858
Trauma and posttraumatic stress disorder in severe mental illness.
Mueser, K. T., Goodman, L. B., Trumbetta, S. L., Rosenberg, S. D., Osher, F. C., Vidaver, R., Auciello, P., & Foy, D. W. (1998) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.66.3.493 · Cited by 790
Goldstein, R. B., Smith, S. M., Chou, S. P., Saha, T. D., Jung, J., Zhang, H., Pickering, R. P., Ruan, W. J., Huang, B., & Grant, B. F. (2016) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-016-1208-5 · Cited by 651 · cited 1×
“In addition, self-medication (e.g. with opioids, cannabis, alcohol) may be common among patients with PTSD [34,35], and the extent to which these medications or substances affect treatment use and outcome in the current study population cannot be determined.”
BackgroundThe long-term costs of traumatic stress: intertwined physical and psychological consequences
McFARLANE, A. C. (2010) · World Psychiatry · doi:10.1002/j.2051-5545.2010.tb00254.x · Cited by 607 · cited 1×
“…symptoms and frequent psychiatric comorbidities could be present for years after the traumatic event prior to a formal PTSD diagnosis [15–17 ,30 ,31 ], during which The barriers to an accurate and timely PTSD diagnosis may also be attributable to the lack of disclosure of trauma history by…”
BackgroundPosttraumatic Stress Disorder in Adults: Impact, Comorbidity, Risk Factors, and Treatment
Sareen, J. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405900902 · Cited by 467
Cited by
Davis, L. L., Behl, S., Lee, D. J., Zeng, H., Skubiak, T., Weaver, S., Hefting, N., Larsen, K. G., & Hobart, M. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.3996 · Cited by 22
Self-citationBrubaker, M., Kapadia, S., Maletic, V., Chambers, J., Watling, C., & Citrome, L. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s501207 · Cited by 7
Stanicic, F., Zah, V., Grbic, D., de Angelo, D., & Bibeau, W. S. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0058 · Cited by 5
Patient journey of civilian adults diagnosed with posttraumatic stress disorder—A chart review study
Davis, L. L., Urganus, A., Gagnon‐Sanschagrin, P., Maitland, J., Bedard, J., Bellefleur, R., Cloutier, M., Guérin, A., & Aggarwal, J. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2308016 · Cited by 3
“Moreover, while the most frequently prescribed first-line pharmacological treatment was SSRI monotherapy, the use of AA monotherapy and combinations were also common, a finding that is consistent with previous studies 19,32 .”
ResultSelf-citationKotochinsky, M., Alessi, M. R., Vieira, G. H., Balogun, M., Sherpa, N. N., & Lezana, A. G. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.10.063 · Cited by 1
Metadata
- Authors
- Davis, L. L., Urganus, A., Gagnon-Sanschagrin, P., Maitland, J., Qu, W., Cloutier, M., Guérin, A., & Aggarwal, J.
- Affiliations
- Tuscaloosa VA Medical Center (US)
- Lundbeck (United States) (US)
- Analysis Group, Inc, Montréal, Canada
- Otsuka (United States) (US)
- Corresponding author
- Maitland, Jessica
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2023-10-17
- Volume
- 39
- Issue
- 11
- Pages
- 1523-1532
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W4387515865
- Cited by
- 6
- References
- 27
- Citations by year
- 2025: 3 · 2024: 3
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Current Medical Research and Opinion (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Otsuka Pharmaceutical
- H. Lundbeck A/S
- Topics
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Clinical Psychology › Migration, Health and Trauma
- Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
- Keywords
- post-traumatic stress disorder, PTSD diagnosis, psychiatric comorbidity, healthcare resource utilization, health care costs, atypical antipsychotics, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, psychotherapy, patient monitoring
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Adult, Female, Humans, Male, Middle Aged, Patient Acceptance of Health Care, Retrospective Studies, Stress Disorders, Post-Traumatic, Antipsychotic Agents, United States, Comorbidity, Health Care Costs, Selective Serotonin Reuptake Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patient journey before and after a formal post-traumatic stress disorder diagnosis in adults in the United States-a retrospective claims study. https://app.cochat.ai/papers/10.1080/03007995.2023.2269839
- The paper
- Davis, L. L., Urganus, A., Gagnon-Sanschagrin, P., Maitland, J., Qu, W., Cloutier, M., Guérin, A., & Aggarwal, J. (2023). Patient journey before and after a formal post-traumatic stress disorder diagnosis in adults in the United States-a retrospective claims study. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2023.2269839
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.